Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 7/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380399 | 1.00 | KMT2A (0.44) | KMT2ADRD2EPHX1BTKPBK | |
| SCHEMBL18534331 | 0.87 | EPHX1 (0.52) | KMT2ADRD2EPHX1BTKPBK | |
| SCHEMBL4920988 | 0.84 | KMT2A (0.50) | KMT2ADRD2EPHX1BTKPBK | |
| SCHEMBL4921002 | 0.84 | KMT2A (0.50) | KMT2ADRD2EPHX1BTKPBK | |
| SCHEMBL6154180 | 0.84 | KMT2A (0.50) | KMT2ADRD2EPHX1BTKPBK | |
| SCHEMBL13135484 | 0.84 | KMT2A (0.47) | KMT2ADRD2EPHX1BTKPBK | |
| SCHEMBL7580702 | 0.84 | BTK (0.50) | KMT2ADRD2EPHX1BTKKDM1A | |
| SCHEMBL1862470 | 0.84 | BTK (0.50) | KMT2ADRD2EPHX1BTKKDM1A | |
| SCHEMBL2300276 | 0.84 | BTK (0.50) | KMT2ADRD2EPHX1BTKKDM1A | |
| SCHEMBL28722421 | 0.82 | DRD2 (0.45) | KMT2ADRD2EPHX1BTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306372-B1 | HETEROCYCLE DERIVATIVES AND DRUGS | NIPPON SHINYAKU CO LTD (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-6794389-B2 | Quinazoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20030119855-A1 | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1306372-A1 | HETEROCYCLE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119855-A1 | Heterocycle derivatives and drugs | OPRL1, OPRK1, OPRD1 | KMT2A 2295/4885DRD2 382/4885EPHX1 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.